Abstract:Junling Li Wei Li Xiaojian Dai Dafang Zhong Yaping Ding Xiaoyan Chen 1College of Sciences, Shanghai University, Shanghai, People’s Republic of China; 2Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People’s Republic of China Background and objective: Paclitaxel protein-bound particles for injectable suspension (nab-paclitaxel) showed many advantages in safety, effectiveness, and convenience. Different from conventional formulations, the bioequivalence evaluation of nab-paclitaxel formulations requires to determine the total amount of paclitaxel in plasma and the unbound paclitaxel to reflect their in vivo disposition. This study aimed to develop an analytical method to quantify the total and unbound paclitaxel in plasma and evaluate the bioequivalence of two formulations of nab-paclitaxel in patients with breast cancer. Materials and methods: An open-label, randomized, two-period crossover study was completed among 24 Chinese patients with breast cancer. The patients were randomized to receive either the test formulation on cycle 1 day 1 and after 21 days in cycle 2 day 1 by the reference formulation (Abraxane®), or vice versa. Rapid equilibrium dialysis was adopted to separate the unbound paclitaxel in human plasma. Total and unbound paclitaxel concentrations were measured by the validated liquid chromatography–tandem mass spectrometry methods over the range of 5.00–15,000 and 0.200–200 ng/mL, respectively. The bioequivalence of the test formulation to the reference formulation was assessed using the Food and Drug Administration and European Medicines Agency guidelines. Results: All the 90% confidence intervals (CIs) of the geometric mean ratios fell within the predetermined acceptance range. The 90% CIs for the area under the concentration–time curve (AUC) from 0 h to 72 h (AUC0–t), AUC from time zero to infinity (AUC0–∞), and peak plasma concentrations (Cmax) for total paclitaxel were 92.03%–98.05%, 91.98%–99.37%, and 91.37%–99.36%, respectively. The 90% CIs of AUC0–t, AUC0–∞, and Cmax for unbound paclitaxel were 86.77%–97.88%, 86.81%–97.88%, and 87.70%–98.86%, respectively. Conclusion: Bioequivalence between the two nab-paclitaxel formulations was confirmed for total and unbound paclitaxel at the studied dose regimen.

Comparison the pharmacokinetics of nanoparticle albumin bound paclitaxel and solvent based paclitaxel in breast cancer patients

Potentially Overestimated Efficacy of Nanoparticle Albumin-bound Paclitaxel compared with Solvent-based Paclitaxel in Breast Cancer: A Systemic Review and Meta-analysis

Superior efficacy of a Cremophor-free albumin-bound paclitaxel compared with solvent-based paclitaxel in Chinese patients with metastatic breast cancer (vol 3, pg 165, 2009)

Cost-minimization Analysis of Albumin-bound Paclitaxel vs. Solvent-based Paclitaxel in the Treatment for Metastatic Breast Cancer

Quantification of paclitaxel in rat plasma by LC-MS/MS and pharmacokinetics of paclitaxel thermosensi-tive liposomes in rats

Randomized Controlled Comparative Clinical Pharmacokinetic Study of Nab-Paclitaxel and Solvent-Based Paclitaxel in Chinese Patients (pts) with Metastatic Breast Cancer (MBC)

Superior Efficacy of a Cremophor‐free Albumin‐bound Paclitaxel Compared with Solvent‐based Paclitaxel in Chinese Patients with Metastatic Breast Cancer

Effects of liposomal paclitaxel and paclitaxel in treatment of non-small-cell lung cancer(64 patients) and breast cancer(62 patients)

Differences in Fatty Acid Oxidation between Nab -Paclitaxel- and Solvent-Based Paclitaxel-Treated A549 Cells Based on Metabolomics

Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis

Bioequivalence of Paclitaxel Protein-Bound Particles in Patients with Breast Cancer: Determining Total and Unbound Paclitaxel in Plasma by Rapid Equilibrium Dialysis and Liquid Chromatography–tandem Mass Spectrometry

Dddt_a_200679 1739..1749

Research progress on nanoparticle albumin-bound paclitaxel

[Study of Bioequiavailability of Paclitaxel for Injection (albumin Bound) and Abraxane and the Efficacy of Extension Treatments in Patients with Metastatic Breast Cancer].

Randomized Study Comparing Nab-Paclitaxel With Solvent- Based Paclitaxel In Chinese Patients (Pts) With Metastatic Breast Cancer (Mbc)

The Anti-Tumor Effects of Lung Cancer-Targeting Long-Circulating Paclitaxel-Containing Liposomes

Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer

Pharmacokinetics research on paclitaxel nano-liposomes in rats

Efficacy of two-weekly nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy for breast cancer.

Clinical study of albumin-bound paclitaxel-based chemotherapy in treatment of advanced breast cancer

Preparation and characterization of paclitaxel palmitate albumin nanoparticles with high loading efficacy: an in vitro and in vivo anti-tumor study in mouse models